文献速递甲状腺核医学

原发性甲状旁腺功能亢进症中功能亢进甲状旁腺术前定位困难时18F-氟胆碱PET/CT的附加价值

Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-04-22

研究纳入27例原发性甲状旁腺功能亢进症且术前定位困难的患者,评估18F-氟胆碱PET/CT的附加价值。18F-FCH PET/CT在24/27例患者中阳性,21例手术患者中19例(90%)甲状旁腺功能亢进症缓解;每患者灵敏度81%、阳性预测值94%,每腺体灵敏度76%、阳性预测值85%、特异度91%、阴性预测值86%,并发现8个99mTc-sestaMIBI闪烁显像与颈部超声均未检出的病灶。

要点

  • 18F-FCH PET/CT在24/27例术前定位困难的原发性甲状旁腺功能亢进症患者中呈阳性。
  • 21例手术患者切除27个病灶,19/21例(90%)甲状旁腺功能亢进症缓解。
  • 每患者灵敏度81%、阳性预测值94%;每腺体灵敏度76%、阳性预测值85%、特异度91%、阴性预测值86%。

核心结论

  • 18F-FCH PET/CT对于标准影像不能确定、术后复发或怀疑多腺体病变等术前定位困难的功能亢进甲状旁腺是有前景的检查方法。

研究设计与样本

  • 连续纳入27例原发性甲状旁腺功能亢进症患者(19例女性;中位年龄58岁),均存在标准术前定位不确定、既往手术甲状旁腺功能亢进症复发或家族性甲状旁腺功能亢进症怀疑多腺体病变。
  • 以组织学所见和甲状旁腺功能亢进症缓解作为金标准。

主要发现

  • 18F-FCH PET/CT在24/27例患者中阳性。
  • 21例患者接受手术,切除27个病灶(14个腺瘤、11个增生腺体、2个功能亢进但组织学正常的腺体),19/21例(90%)甲状旁腺功能亢进症缓解。
  • 18F-FCH PET/CT在17/21例患者中定位22个病灶;每患者灵敏度81%、阳性预测值94%;每腺体灵敏度76%、阳性预测值85%、特异度91%、阴性预测值86%。
  • 18F-FCH PET/CT发现8个99mTc-sestaMIBI闪烁显像与颈部超声均未检出的病灶。
  • 在家族性甲状旁腺功能亢进症和/或多腺体病变患者中,每患者分析灵敏度100%、每腺体分析灵敏度79%,阴性预测值63%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the added value of 18F-Fluorocholine (18F-FCH) PET/CT in presurgical imaging of patients with primary hyperparathyroidism (HPT) and challenging localization of the hyper-functioning parathyroid glands. METHODS: We included 27 consecutive patients with primary HPT (19 F; median age: 58 years), with either (i) non-conclusive pre-surgical localization with 99mTc-sestaMIBI scintigraphy and neck ultrasonography (US), (ii) recurrence of previously operated HPT, or (iii) familiar HPT with a suspicion of multiple gland disease. Histological findings and resolution of HPT were considered as the gold standard. RESULTS: 18F-FCH PET/CT was positive in 24/27 patients. Twenty-one patients underwent surgery with 27 resected lesions (14 adenomas, 11 hyperplastic glands, two hyper-functioning histologically normal glands), with resolution of HPT in 19/21 patients (90%). 18F-FCH PET/CT localized 22 lesions in 17/21 patients (per patient: sensitivity 81%, positive predictive value (PPV) 94%; per gland: sensitivity 76%, PPV 85%, specificity 91%, negative predictive value (NPV) 86%). 18F-FCH PET/CT found eight lesions which were undetectable on both 99mTc-sestaMIBI scintigraphy and US. In patients with a familial HPT and/or a multiple gland disease, sensitivity was 100 and 79% on a per-patient and a per-gland analysis respectively, while NPV was 63%. In six patients with a persistence or recurrence of previously treated HPT, 18F-FCH PET/CT localized all lesions, both in sporadic and familiar disease. CONCLUSIONS: 18F-FCH PET/CT is a promising modality in challenging pre-surgical localization of hyper-functioning parathyroid glands, such as inconclusive standard imaging, recurrence after surgery, or suspected multiple gland disease.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Grimaldi S, Young J, Kamenicky P, et al. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. Eur J Nucl Med Mol Imaging. 2018. PMID: 29680989. doi:10.1007/s00259-018-4018-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。